Dr. Hirva Mansurali Mamdani, MD

Dr. Mamdani practices at McLaren Flint Hospital in Flint, Michigan.

Dr. Mamdani's NPI, 1437446820, was assigned on July 6, 2011. Dr. Mamdani holds Michigan license 4301098222.

Dr. Mamdani's primary practice is McLaren Flint Hospital, at 401 S Ballenger Hwy, Flint, MI 48532 in Genesee County. The practice phone is (810) 762-6699.

Dr. Mamdani's primary practice is McLaren Flint Hospital in Flint, Michigan. Dr. Mamdani is also affiliated with DMC Harper University Hospital. The medical group on file is Barbara Ann Karmanos Cancer Institute. Dmand AI also links Dr. Mamdani to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mamdani practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mamdani's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mamdani is licensed in Michigan.

CMS data shows 282 Medicare services from Dr. Mamdani across 4 procedure codes in 2024, all of them office visits, for 109 Medicare patients. Medicare paid $25,041 for them.

CMS counts 109 Medicare patients who saw Dr. Mamdani in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have cancer, and 75% have high blood pressure. 35% are also on Medicaid. Their average risk score is 3.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mamdani's median patient age at 69, with 57% women.

In 2024, Dr. Mamdani wrote 294 Medicare Part D claims for 82 patients. 74% of them were for generic drugs. CMS names the drug for 129 of them, across 7 drugs with 11 or more claims each, at $573,827 in total drug cost. In 2023, CMS named 129 claims across 7 drugs.

Dr. Mamdani accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 55 papers to Dr. Mamdani, published from 2015 to 2025. 2022 was the busiest year, with 10. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Mamdani has published most often in Clin Lung Cancer. Dr. Mamdani's most frequent co-authors are Shadia I. Jalal, MD, Dipesh Uprety, MD and Gerold Bepler, MD.

Dmand AI links Dr. Mamdani to 10 clinical trials, 6 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Small Cell Lung Carcinoma. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 65 general payments to Dr. Mamdani from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. AstraZeneca Pharmaceuticals LP paid the most, $21,309. It also lists 1 research payment totaling $3,200 in 2023.